AstraZeneca plans a direct NYSE listing by 2026 while staying on LSE, boosting U.S. investment and cutting drug prices. Read ...
The British company said the direct listing would replace the existing listing of its American depository receipts on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback